Results 221 to 230 of about 56,162 (258)
Some of the next articles are maybe not open access.
JAK Inhibitor in CALR-Mutant Myelofibrosis
New England Journal of Medicine, 2014na
PASSAMONTI, FRANCESCO +2 more
openaire +6 more sources
Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire +2 more sources
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire +2 more sources
Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire +1 more source
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire +1 more source
[JAK Inhibitors in Rheumatology].
Deutsche medizinische Wochenschrift (1946), 2019In Germany, baricitinib and tofacitinib have been approved for the treatment of at least moderately active rheumatoid arthritis after the failure of conventional disease modifying anti-rheumatic drugs in 2017, and tofacitinib also for psoriatic arthritis and ulcerative colitis. Both baricitinib and tofacitinib can be taken orally and reversibly inhibit
openaire +2 more sources
Successful Treatment of Granulomatous Rosacea by JAK Inhibitor Abrocitinib: A Case Report
Clinical, Cosmetic and Investigational Dermatology, 2023Mingyang Ren, Xianhong Yang, Yan Teng
exaly
Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs
Current Medicinal Chemistry, 2022Guo-Wu Rao, Min-Yan Zhao, Wen Zhang
exaly
JAK Inhibitors in Cytokine Storm Syndromes
Cytokine storm syndromes (CSSs) comprise a group of severe and often fatal hyperinflammatory conditions driven by the overproduction of pro-inflammatory cytokines by activated cells of the immune system. Many of the CSS-associated cytokines mediate their downstream effects by signaling through the Janus kinases (JAKs) and signal transducers and ...Camille, Keenan +3 more
openaire +2 more sources
Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor
Bioorganic and Medicinal Chemistry Letters, 2022Archana Gite
exaly